By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cascadian Therapeutics (Formally known as Oncothyreon) 

2601 Fourth Avenue
Suite 500
Seattle  Washington  98121   U.S.A.
Phone: 206-801-2100 Fax: 206-801-2101



Company News
Cascadian Therapeutics (ONTY) Announces Poster Presentations On Tucatinib At The European Society Of Medical Oncology (ESMO) 2016 Congress 9/28/2016 7:30:23 AM
Cascadian Therapeutics (ONTY) To Present At The Rodman & Renshaw 18th Annual Global Investment Conference 9/6/2016 8:33:32 AM
Cascadian Therapeutics (ONTY) Announces Approval Of Nonproprietary Name “Tucatinib” For Lead Product Candidate ONT-380 9/1/2016 7:57:02 AM
Cascadian Therapeutics (ONTY) Reports Second Quarter 2016 Financial Results And Provides Corporate Update 8/9/2016 8:35:47 AM
Cascadian Therapeutics (ONTY) Announces Exercise Of Underwriters' Over-Allotment Option And Closing Of $46.0 Million Concurrent Offerings Of Common Stock And Series D Convertible Preferred Stock 6/29/2016 10:34:25 AM
Cascadian Therapeutics (ONTY) Receives ONT-380 Fast Track Designation From FDA For The Treatment Of Advanced HER2+ Metastatic Breast Cancer 6/29/2016 10:33:19 AM
Cascadian Therapeutics (ONTY) Announces Proposed Public Offering 6/23/2016 7:38:39 AM
Cascadian Therapeutics (ONTY) Reports Topline ONT-380 "Triplet" Data and Outlines Key Development Strategies 6/14/2016 11:06:29 AM
Oncothyreon Announces Corporate Name Change To Cascadian Therapeutics (ONTY) 6/8/2016 7:53:05 AM
ASCO2016: Oncothyreon (ONTY) Presents Phase Ib Results Of ONT-380 In Combination With T-DM1 In HER2+ Metastatic Breast Cancer At ASCO 6/6/2016 3:48:13 PM